| [Flash Point] 274 | |
| [Fire Fighting] Wear SCBA and protective clothing. Use extinguishing media most appropriate for surrounding fire. | |
| [Ingestion] Wash mouth out with water. Seek medical aid. | |
| [Inhalation] Remove to fresh air. Seek medical aid. | |
| [Skin] Flush skin with water. Seek medical aid. | |
| [Eyes] Flush eyes with water. Seek medical aid. | |
| [Storage] Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Personal Protection] Latex gloves, safety goggles, disposable protective apparel. | |
| [Respirators] NIOSH approved respirator. | |
| [Exposure Effects] Abnormally low blood pressure may develop in adults and children who have ingested an overdose of haloperidol. One pediatric case of elevated blood pressure following overdose has been reported. Elevated body temperature has both been associated with haloperidol therapy and may occur with overdose. Respiratory depression may occur. haloperidol - severe extrapyramidal effects may follow overdose. Irreversible tardive dyskinesia has been reported with therapeutic use and may occur with overdose. Seizures have been reported with pediatric overdose. Neuroleptic malignant syndrome has been rarely reported in adults and children. Droperidol - extrapyramidal effects have been reported following droperidol therapy. Neuroleptic malignant syndrome has been reported in adults and children. | |
| [Appearance] Clear, colorless solution with no odor. | |
| [Solubility in water] 14 mg/L | |
| [Melting Point] 147 | |
| [Boiling Point] 529 | |
| [Vapor Pressure] 5E-12 (25 C) | |
| [Density] 1.3 g/cm3 (20 C) | |
| [pKa/pKb] 5.75 (pKb) | |
| [Partition Coefficient] 3.36 | |
| [Heat Of Vaporization] 84.6 kJ/mol | |
| [Usage] Medication (vet). | |
| [Product Name] 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone | |
| [Synonyms] 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone 4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one Aloperidin Aloperidolo Aloperidon gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone | |
| [CAS] "CASEN_52-86-8.htm">52-86-8 | |
| [Formula] C21H23ClFNO2 | |
| [Molecular Weight] 375.87 | |
| [EINECS] 200-155-6 | |
| [RTECS] EU1575000 | |
| [RTECS Class] Tumorigen; Drug; Mutagen; Reproductive Effector; Human Data | |
| [Merck] 12,4629 | |
| [Beilstein/Gmelin] 331267 | |
| [Beilstein Reference] 5-21-02-00377 | |
| [Small spills/leaks] Wear recommended protective equipment. Sweep up material or absorb with paper towels. Place in appropriate container for disposal. | |
| [Stability] Stable at normal temperature and pressure. |
Print